down arrow

Pulmonx Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7458481014
USD
2.14
0.39 (22.29%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.852.16

52 Week

1.319.37
Valuation
Technical
Day's Volume

CASH

994.75 k

Shareholding (Mar 2025)

FII

14.27%

Held by 63 FIIs

DII

32.87%

Held by 50 DIIs

Promoter

7.55%

How big is Pulmonx Corp.?

22-Jun-2025

As of Jun 18, Pulmonx Corp. has a market capitalization of 109.10 million, with net sales of 87.48 million and a net profit of -57.10 million over the last four quarters. Shareholder's funds are reported at 85.81 million, and total assets amount to 167.71 million.

As of Jun 18, Pulmonx Corp. has a market capitalization of 109.10 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 87.48 million, while the sum of net profit for the same period is -57.10 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 85.81 million, and total assets amount to 167.71 million.

Read More

What does Pulmonx Corp. do?

22-Jun-2025

Pulmonx Corporation is a medical technology company specializing in treatments for obstructive lung disease, with recent net sales of $23 million and a net loss of $14 million. It has a market cap of $109.10 million and key metrics indicating it is currently loss-making.

Overview:<BR>Pulmonx Corporation is a commercial-stage medical technology company focused on providing planning tools and treatments for obstructive lung disease within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 23 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -14 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 109.10 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.65 <BR>Return on Equity: -71.30% <BR>Price to Book: 1.40<BR><BR>Contact Details:<BR>Address: 700 Chesapeake Dr, REDWOOD CITY CA: 94063 <BR>Tel: 1 650 3640400 <BR>Fax: 1 302 6555049

Read More

Should I buy, sell or hold Pulmonx Corp.?

22-Jun-2025

Who are in the management team of Pulmonx Corp.?

22-Jun-2025

As of March 2022, the management team of Pulmonx Corp. includes Chairman Dana Mead, President and CEO Glendon French, and Directors Thomas Burns and Georgia Garinois-Melenikiotou.

As of March 2022, the management team of Pulmonx Corp. includes Mr. Dana Mead, who serves as the Chairman of the Board, and Mr. Glendon French, who is the President, Chief Executive Officer, and a Director. Additionally, the Board of Directors comprises Mr. Thomas Burns and Ms. Georgia Garinois-Melenikiotou, both serving as Directors.

Read More

Is Pulmonx Corp. technically bullish or bearish?

20-Sep-2025

As of August 26, 2025, Pulmonx Corp. shows a mildly bearish trend with mixed signals from technical indicators, significantly underperforming the S&P 500 with a year-to-date return of -76.44% compared to the S&P's 12.22%.

As of 26 August 2025, the technical trend for Pulmonx Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearishness and the weekly KST and OBV also showing bearish signals. However, the weekly MACD and RSI are mildly bullish and bullish respectively, suggesting some positive momentum. The Bollinger Bands are bearish on both weekly and monthly time frames. <BR><BR>In terms of performance, Pulmonx Corp. has significantly underperformed against the S&P 500, with a year-to-date return of -76.44% compared to the S&P 500's 12.22%, and a one-year return of -80.95% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Jun 25

  • ROCE(HY) Lowest at -66.88%
  • DEBT-EQUITY RATIO (HY) Highest at -40.03 %
  • OPERATING PROFIT(Q) Lowest at USD -14.41 MM
2

Risky - Negative EBITDA

3

High Institutional Holdings at 100%

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 69 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.67

stock-summary
Return on Equity

-82.41%

stock-summary
Price to Book

1.00

Revenue and Profits:
Net Sales:
24 Million
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.92%
0%
28.92%
6 Months
-32.7%
0%
-32.7%
1 Year
-67.62%
0%
-67.62%
2 Years
-80.94%
0%
-80.94%
3 Years
-67.13%
0%
-67.13%
4 Years
-92.8%
0%
-92.8%
5 Years
-95.85%
0%
-95.85%

Pulmonx Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Pulmonx Corp. technically bullish or bearish?

As of 26 August 2025, the technical trend for Pulmonx Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearishness and the weekly KST and OBV also showing bearish signals. However, the weekly MACD and RSI are mildly bullish and bullish respectively, suggesting some positive momentum. The Bollinger Bands are bearish on both weekly and monthly time frames. In terms of performance, Pulmonx Corp. has significantly underperformed against the S&P 500, with a year-to-date return of -76.44% compared to the S&P 500's 12.22%, and a one-year return of -80.95% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
23.33%
EBIT Growth (5y)
-174.48%
EBIT to Interest (avg)
-28.26
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.54
Tax Ratio
0.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.64
EV to EBIT
-1.37
EV to EBITDA
-1.41
EV to Capital Employed
2.85
EV to Sales
0.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-207.42%
ROE (Latest)
-71.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 37 Schemes (45.31%)

Foreign Institutions

Held by 63 Foreign Institutions (14.27%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 14.90% vs 20.93% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.65% vs 5.56% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "23.90",
          "val2": "20.80",
          "chgp": "14.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.40",
          "val2": "-13.50",
          "chgp": "-6.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.90",
          "chgp": "-11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.20",
          "val2": "-15.30",
          "chgp": "0.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-620.50%",
          "val2": "-669.10%",
          "chgp": "4.86%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.98% vs 27.93% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.24% vs -3.23% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "83.80",
          "val2": "68.70",
          "chgp": "21.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.40",
          "val2": "-60.00",
          "chgp": "9.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.50",
          "val2": "3.20",
          "chgp": "9.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-56.40",
          "val2": "-60.80",
          "chgp": "7.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-668.20%",
          "val2": "-901.90%",
          "chgp": "23.37%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
23.90
20.80
14.90%
Operating Profit (PBDIT) excl Other Income
-14.40
-13.50
-6.67%
Interest
0.80
0.90
-11.11%
Exceptional Items
0.00
-1.70
100.00%
Consolidate Net Profit
-15.20
-15.30
0.65%
Operating Profit Margin (Excl OI)
-620.50%
-669.10%
4.86%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 14.90% vs 20.93% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 0.65% vs 5.56% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
83.80
68.70
21.98%
Operating Profit (PBDIT) excl Other Income
-54.40
-60.00
9.33%
Interest
3.50
3.20
9.37%
Exceptional Items
-1.70
0.00
Consolidate Net Profit
-56.40
-60.80
7.24%
Operating Profit Margin (Excl OI)
-668.20%
-901.90%
23.37%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 21.98% vs 27.93% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.24% vs -3.23% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Pulmonx Corp. stock-summary
stock-summary
Pulmonx Corp.
Pharmaceuticals & Biotechnology
Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform. The Company's solutions offer minimally invasive treatment option for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
Company Coordinates stock-summary
Company Details
700 Chesapeake Dr , REDWOOD CITY CA : 94063
stock-summary
Tel: 1 650 3640400
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."